Dr. CHEN Kang
陳康

Field of Research

Gene/Drug targeted delivery, Nanomedicine, Biomaterials

Biography

Dr. Kang Chen received his Ph.D. in Pharmaceutics from Shenyang Pharmaceutical University (ranked No. 1 nationwide in this discipline). His research has long focused on targeted drug and gene delivery technologies, including tumor-targeted, liver-targeted, and adipose tissue–targeted delivery, in order to improve therapeutic efficacy and reduce drug toxicity.

Publications

1. Chen Kang, Gao Yuan, Zhang Yaming, Feng Tianshi, Wang Qin, el at, Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects, Nature Communications, 13, 7838 (2022). 

2. Yang Zhou, Kang Chen, Lin Wing Kak, Jinzhao Liu, Weirong Kang, el at, Photo-enhanced synergistic induction of ferroptosis for anti-cancer immunotherapy, Advanced Health Materials, 2023, 12, 2300994. 

3. Kang Chen, Xiu Xin, Lipeng Qiu, Wenpan Li, el at, Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy. Acta Biomaterialia, 100, 118-131 (2019).

4. Kang Chen, Lingling Guo, Jiulong Zhang, Qing Chen, el at, A gene delivery system containing nuclear localization signal: Increased nucleus import and transfection efficiency with the assistance of RanGAP1. Acta Biomaterialia (IF: 10.63), 215-226 (2017).

5. Kang Chen, Qing Chen, Kuanglei Wang, Jia Zhu, el at, Synthesis and characterization of a PAMAM-OH derivative containing an acid-labile β-thiopropionate bond for gene delivery. International journal of pharmaceutics, 509, 314-327 (2016)